Trial Profile

A Phase 1/2a study of UKK-0018 in peanut-allergic adult subjects

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Jan 2026 New trial record
08 Jan 2026 According to an Ukko media release, the company completed a $45M series C financing. The financing is anticipated to support operations through 2027, including the planned Phase 1/2a trial of UKK-0018.
08 Jan 2026 According to an Ukko media release, the UKK-0018 for peanut allergy has received regulatory clearance in AU and NZ to begin clinical trials in 1H 2026. Ukko plans to initiate a Phase 1/2a study in peanut-allergic adult subjects in the 1H 2026 with initial data anticipated in early 2027. The trial will enroll approximately 32-40 subjects across 5-6 sites in Australia and New Zealand.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com